Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patientsLeonora W. de Boo, Sabine C. Linn, Roelof J.C. Kluin et al.|British Journal of Cancer|2022Cited by 41
Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, Heather Ann Brauer et al.|Clinical Cancer Research|2020Cited by 41
Adjuvant Capecitabine-Containing Chemotherapy Benefit and Homologous Recombination Deficiency Status Among Early-Stage TNBC Patients in the FinXX trialLeonora W. de Boo, Sabine C. Linn, Mark Opdam et al.|Research Square|2020Cited by 1
Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial).Saranya Chumsri, E. Aubrey Thompson, Karama Asleh et al.|Journal of Clinical Oncology|2019Cited by 1
Supplementary Figure S2 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, Heather Ann Brauer et al.|Unknown|2023Cited by 0